Europe funds R&D (research and development) programme:
This article was originally published in Clinica
The European Parliament has endorsed a compromise version of the fifth framework programme on research spending in the EU, following a final round of conciliation talks between the Parliament and the Council. The final budget has been set at ECU14.96 billion ($16.7 billion), an increase of 4.6%, with the largest sectoral increase (42%) going to the biosciences. Parliament rejected an attempt by the Greens to refuse funding for research based on using foetal tissues and pre-implantation diagnosis "until the ethical issues have been fully and publicly evaluated".
You may also be interested in...
By establishing a dedicated consumer healthcare subsidiary, Norgine is hoping it can grow its $200m-plus Movicol laxative brand and take advantage of M&A opportunities in the OTC market.
The AAM has insisted that the US Supreme Court should uphold the inter partes review framework, in an amicus brief filed as part of litigation that potentially threatens hundreds of IPR decisions.
The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.